KR20240013793A - 조합 요법을 사용하는 다발성 골수종의 치료 방법 - Google Patents

조합 요법을 사용하는 다발성 골수종의 치료 방법 Download PDF

Info

Publication number
KR20240013793A
KR20240013793A KR1020237044752A KR20237044752A KR20240013793A KR 20240013793 A KR20240013793 A KR 20240013793A KR 1020237044752 A KR1020237044752 A KR 1020237044752A KR 20237044752 A KR20237044752 A KR 20237044752A KR 20240013793 A KR20240013793 A KR 20240013793A
Authority
KR
South Korea
Prior art keywords
days
administered
compound
day
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237044752A
Other languages
English (en)
Korean (ko)
Inventor
파울로 체사르 마차그
테레사 펠루소
Original Assignee
셀진 코포레이션
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀진 코포레이션, 브리스톨-마이어스 스큅 컴퍼니 filed Critical 셀진 코포레이션
Publication of KR20240013793A publication Critical patent/KR20240013793A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237044752A 2021-05-27 2022-05-26 조합 요법을 사용하는 다발성 골수종의 치료 방법 Pending KR20240013793A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163194026P 2021-05-27 2021-05-27
US63/194,026 2021-05-27
PCT/US2022/031055 WO2022251441A1 (en) 2021-05-27 2022-05-26 Methods of treating multiple myeloma using combination therapy

Publications (1)

Publication Number Publication Date
KR20240013793A true KR20240013793A (ko) 2024-01-30

Family

ID=82067750

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237044752A Pending KR20240013793A (ko) 2021-05-27 2022-05-26 조합 요법을 사용하는 다발성 골수종의 치료 방법

Country Status (11)

Country Link
US (1) US20240252487A1 (https=)
EP (1) EP4347037A1 (https=)
JP (1) JP2024520435A (https=)
KR (1) KR20240013793A (https=)
CN (1) CN117440828A (https=)
AU (1) AU2022282372A1 (https=)
BR (1) BR112023022679A2 (https=)
CA (1) CA3215840A1 (https=)
IL (1) IL307681A (https=)
MX (1) MX2023012911A (https=)
WO (1) WO2022251441A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
EP4467143B1 (en) * 2017-07-10 2026-03-11 Celgene Corporation Method for preparing 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile
WO2020146441A1 (en) 2019-01-09 2020-07-16 Celgene Corporation Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
FI3908281T3 (fi) 2019-01-09 2024-10-01 Celgene Corp Antiproliferatiivisia yhdisteitä ja toisia aktiivisia aineita käytettäväksi multippelin myelooman hoidossa
SG11202107439XA (en) 2019-01-09 2021-08-30 Celgene Corp Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same

Also Published As

Publication number Publication date
AU2022282372A1 (en) 2023-11-02
WO2022251441A1 (en) 2022-12-01
BR112023022679A2 (pt) 2024-01-23
CA3215840A1 (en) 2022-12-01
EP4347037A1 (en) 2024-04-10
IL307681A (en) 2023-12-01
US20240252487A1 (en) 2024-08-01
MX2023012911A (es) 2023-11-08
CN117440828A (zh) 2024-01-23
JP2024520435A (ja) 2024-05-24

Similar Documents

Publication Publication Date Title
JP7258009B2 (ja) 抗増殖化合物及びその使用方法
JP7853352B2 (ja) 多発性骨髄腫を治療すること及び４－（４－（４－（（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－４－イル）オキシ）メチル）ベンジル）ピペラジン－１－イル）－３－フルオロベンゾニトリルのバイオマーカーの使用
RU2318517C2 (ru) Комбинация, включающая n-{5-[4-(4-метилпиперазинометил)бензоиламидо]-2-метилфенил}-4-(3-пиридил)-2-пиримидинамин и химиотерапевтический агент
KR20180022926A (ko) 암 치료를 위한 hdac 억제제와 항-pd-l1 항체의 조합
Kubo et al. Study protocol: Phase-Ib trial of nivolumab combined with metformin for refractory/recurrent solid tumors
AU2019277632A1 (en) Biomarker for judging efficacy of immune checkpoint inhibitor
US20200268847A1 (en) Methods of Treating Newly Diagnosed Multiple Myeloma with a Combination of An Antibody that Specifically Binds CD38, Lenalidomide and Dexamethasone
JP2019011376A (ja) ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ
JP2022516974A (ja) 多発性骨髄腫の治療における抗増殖化合物及び第２の活性薬剤とそれらの併用方法
KR20220107182A (ko) 2-(4-클로로페닐)-n-((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-5-일)메틸)-2,2-디플루오로아세트아미드에 대한 임상 민감도를 예측하기 위한 바이오마커의 용도
JP2018138570A (ja) 癌の治療のためのａｍｇ９００の使用
JP2022504468A (ja) 転移性膵臓腺癌の処置
EP3914257B1 (en) Combination of a bcl-2/bcl-xl inhibitor with osimertinib
UA126313C2 (uk) Комбінована терапія
KR20240013793A (ko) 조합 요법을 사용하는 다발성 골수종의 치료 방법
US20250186393A1 (en) Treatment of breast cancer with amcenestrant
WO2024155790A2 (en) Novel approach for treatment of cancer using immunomodulation
CN104334192A (zh) 使用pi3k抑制剂和mek抑制剂治疗癌症的方法
KR20250095627A (ko) 에스트로겐 수용체-매개 장애의 치료 방법
WO2024076633A1 (en) Methods of treating estrogen receptor-mediated disorders
WO2024015506A1 (en) Methods of treating estrogen receptor-mediated disorders
CN118804747A (zh) 用安森司群治疗乳腺癌
CA3269490A1 (en) Methods of treating estrogen receptor-mediated disorders
CN116370607A (zh) 人重组hmgb1在制备治疗胶质瘤化疗增敏剂中的应用
KR20210097139A (ko) 데비미스타트를 사용하는 급성 골수성 백혈병을 치료하기 위한 치료적 방법 및 조성물

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231226

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250523

Comment text: Request for Examination of Application